Circulating Tumor DNA in Surgical Lung Cancer Patients

Shenzhen Gene Health Bio Tech

Status: Unknown

Conditions: Lung Neoplasms

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03081741

GeneHealth-LC-01

Details and patient eligibility

About

Conduct a prospective study to detect the change of ctDNA of surgical lung cancer patients.

Full description

Studies have shown the feasibility of detecting mutation status by blood circulating tumor DNA (ctDNA) in lung cancer patients.

The investigators plan to test the blood ctDNA in surveillance of surgical lung cancer patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.

Enrollment: 500 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Aged 18 to 80 years Undergo radical surgery Histologically confirmed diagnosis of lung cancer Considered primary lung cancer by clinical criteria Patients must have given written informed consent

Exclusion criteria

Unable to comply with the study procedure Malignant tumor history Patients who received any treatment prior to resection Unqualified blood samples